1. The pharmacokinetics of orally administered fudosteine in healthy Chinese volunteers
HY JIAO, ZJ ZHANG*. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS 2006, Vol. 31, No.2, pp.65-72
In preclinical experimental studies with rats, this drug has been characterized as inhibiting hyperplasia of goblet cells induced by bacterial endotoxin and isoproterenol. However, the mechanism of action of fudosteine has not been clarified. Although goblet cells are important front-line defenders of the airways, several chronic respiratory diseases induce mucus hypersecretion, which is caused by an increase in the number of goblet cells in response to chronic airway insult . In rats, the increase in goblet cell number in the tracheal epithelium is induced by the intratracheal uptake of bacterial endotoxin. Recently, Komatsu et al. found that the increase in neutrophil chemoattractant levels, followed by neutrophil migration into the airway epithelium play an important role in increasinggoblet cellnumber in bacterial endotoxin- inducedairway inflammation, and that the inhibitory effects of fudosteine on neutrophil chemoattractant production and/or neutrophil migration may participate in the inhibition of goblet cell hyperplasia. Up to now, no clinical pharmacokinetic study on fudosteine has been reported. The main objective of this paper was to investigate the pharmacokinetics of fudosteine in healthy Chinese volunteers after single- and multiple-dose oral administration. Gender differences were also compared after single- and multiple-dose oral administration.